Expleo Solutions Valuation

Is EXPLEOSOL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EXPLEOSOL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EXPLEOSOL (₹1363.35) is trading below our estimate of fair value (₹5325.24)

Significantly Below Fair Value: EXPLEOSOL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EXPLEOSOL?

Key metric: As EXPLEOSOL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EXPLEOSOL. This is calculated by dividing EXPLEOSOL's market cap by their current earnings.
What is EXPLEOSOL's PE Ratio?
PE Ratio	19.4x
Earnings	₹1.09b
Market Cap	₹20.31b

EXPLEOSOL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.7x
Enterprise Value/EBITDA	10.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does EXPLEOSOL's PE Ratio compare to its peers?

The above table shows the PE ratio for EXPLEOSOL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	39.8x
501421 TechNVision Ventures	83.8x	n/a	₹19.9b
532365 Dynacons Systems & Solutions	25.6x	n/a	₹16.5b
ACCELYA Accelya Solutions India	22.9x	n/a	₹22.1b
SAKSOFT Saksoft	26.8x	n/a	₹26.6b
EXPLEOSOL Expleo Solutions	19.4x	n/a	₹20.3b

Price-To-Earnings vs Peers: EXPLEOSOL is good value based on its Price-To-Earnings Ratio (19.4x) compared to the peer average (39.8x).

Price to Earnings Ratio vs Industry

How does EXPLEOSOL's PE Ratio compare vs other companies in the IN IT Industry?

4 Companies	Price / Earnings	Estimated Growth	Market Cap
GTL GTL	1.1x	n/a	US$22.47m
517429 Athena Global Technologies	0.6x	n/a	US$15.83m
509040 Netlink Solutions (India)	3.2x	n/a	US$5.54m
512341 CES	0.05x	n/a	US$130.33k

No more companies available in this PE range

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: EXPLEOSOL is good value based on its Price-To-Earnings Ratio (19.4x) compared to the Indian IT industry average (34.3x).

Price to Earnings Ratio vs Fair Ratio

What is EXPLEOSOL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EXPLEOSOL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	19.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EXPLEOSOL's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Cigniti Technologies

₹38.2b

Provides software testing services worldwide.

534758

₹1,452.95

5.9%

26.3%

Bodhtree Consulting

₹151.5m

Bodhtree Consulting Limited, together with its subsidiaries, provides information technology (IT) and IT enabling services primarily in India and the United States.

539122

₹75.90

3.7%

Mindpool Technologies

₹268.0m

Provides IT staffing, software development, and information technology enabled services in India.

MINDPOOL

₹63.25

-23.9%